Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026

Moderna has surged over 600% in 2026, driven by breakthrough Phase 3 trial results for its personalized cancer vaccine (intismeran autogene) combined with Merck's Keytruda, plus FDA approval for its flu vaccine mFLUSIVA. However, despite strong innovation, the stock appears overvalued at a $90 billion market cap with a 45% downside according to Wall Street analysts. The company would need to generate unrealistic revenue levels to justify current valuations, leaving little room for error.